Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
Location: 2265 Upper Middle Road East, Oakville, ON, L6H 0G5, Canada | Website: https://www.cardiolrx.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
90.43M
52 Wk Range
$0.77 - $2.24
Previous Close
$1.08
Open
$1.07
Volume
387,127
Day Range
$1.06 - $1.11
Enterprise Value
74.14M
Cash
18.2M
Avg Qtr Burn
-6.267M
Insider Ownership
4.18%
Institutional Own.
8.48%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CardiolRx™ Details Recurrent pericarditis | Phase 3 Data readout | |
CardiolRx™ Details Acute Myocarditis | Phase 2 Update | |
CardiolRx™ Details COVID-19 | Failed Discontinued |